Protein & Cell >

2019 , Vol. 10 >Issue 12: 902 - 907

DOI: https://doi.org/10.1007/s13238-019-0649-5

LETTER

Continuous culture of urine-derived bladder cancer cells for precision medicine

  • Shuai Jiang 1 ,
  • Jiaqi Wang 2 ,
  • Chen Yang 2 ,
  • Renke Tan 2 ,
  • Jun Hou 3 ,
  • Yuan Shi 3 ,
  • Huihui Zhang 4 ,
  • Shiyu Ma 2 ,
  • Jianan Wang 5 ,
  • Mengmeng Zhang 6 ,
  • George Philips 7 ,
  • Zengxia Li 2 ,
  • Jian Ma 6 ,
  • Wanjun Yu 4 ,
  • Guohua Wang 5 ,
  • Yuanming Wu 8 ,
  • Richard Schlegel 9 ,
  • Huina Wang 6 ,
  • Shanbo Cao 6 ,
  • Jianming Guo , 1 ,
  • Xuefeng Liu , 9 ,
  • Yongjun Dang , 2
Expand
  • 1. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • 2. Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education and Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
  • 3. Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • 4. Department of Respiratory and Critical Care Medicine, Yinzhou Hospital Affiliated to Medical school of Ningbo University, Ningbo 315000, China
  • 5. School of Computer Science and Technology, Harbin Institute of Technology, Harbin 150000, China
  • 6. AcornMed Biotechnology Co., Ltd, Beijing 100176, China
  • 7. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, MedStar Georgetown University Hospital, Washington, DC 20001, USA
  • 8. Department of Biochemistry and Molecular Biology and Center for DNA Typing, Fourth Military Medical University, Xi’an 710000, China
  • 9. Department of Pathology, Center for Cell Reprogramming, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC 20001, USA

Published date: 15 Dec 2019

Copyright

2019 The Author(s)
Fold

Cite this article

Shuai Jiang , Jiaqi Wang , Chen Yang , Renke Tan , Jun Hou , Yuan Shi , Huihui Zhang , Shiyu Ma , Jianan Wang , Mengmeng Zhang , George Philips , Zengxia Li , Jian Ma , Wanjun Yu , Guohua Wang , Yuanming Wu , Richard Schlegel , Huina Wang , Shanbo Cao , Jianming Guo , Xuefeng Liu , Yongjun Dang . Continuous culture of urine-derived bladder cancer cells for precision medicine[J]. Protein & Cell, 2019 , 10(12) : 902 -907 . DOI: 10.1007/s13238-019-0649-5

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Anjanappa M, Hao Y, Simpson ER, Bhat-Nakshatri P, Nelson JB, Tersey SA, Mirmira RG, Cohen-Gadol AA, Saadatzadeh MR, Li L (2018) A system for detecting high impact-low frequency mutations in primary tumors and metastases. Oncogene 37:185–196

DOI

2
Berdik C (2017) Unlocking bladder cancer. Nature 551:S34–S35

DOI

3
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132

DOI

4
Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM (2017) Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer 16:80

DOI

5
Jin L, Qu Y, Gomez LJ, Chung S, Han B, Gao B, Yue Y, Gong Y, Liu X, Amersi F (2018) Characterization of primary human mammary epithelial cells isolated and propagated by conditional reprogrammed cell culture. Oncotarget 9:11503–11514

DOI

6
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet 388:2796–2810

DOI

7
Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ (2004) The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3:279–290

8
Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R (2015) Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med 3:36

9
Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V (2012) ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 180:599–607

DOI

10
Marquart J, Chen EY, Prasad V (2018) Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 4:1093–1098

DOI

11
Rubio-Perez C, Tamborero D, Schroeder MP, Antolin AA, Deu-Pons J, Perez-Llamas C, Mestres J, Gonzalez-Perez A, Lopez-Bigas N (2015) In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27:382–396

DOI

12
Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K (2017) Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer. Eur Urol 71:319–327

DOI

13
Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185

DOI

Options
Outlines

/

〈 〉